AETERNA ZENTARIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.6 CAD | -2.62% |
|
-2.26% | +1.17% |
Presenter SpeechJenene Thomas (Analysts)Good morning, and thank you for joining us for the thi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.17% | 9.19M | |
| +0.17% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.23% | 24.63B | |
| -24.79% | 18.2B | |
| +26.69% | 12.01B | |
| -3.13% | 11.76B | |
| +6.57% | 10.4B | |
| -18.08% | 9.94B |
- Stock Market
- Equities
- AEZS Stock
- News Aeterna Zentaris Inc.
- Transcript : Aeterna Zentaris Inc. - Special Call
